BALTIMORE, June 30 /PRNewswire/ -- GoIndustry DoveBid announces the Pfizer asset disposition program, which will see auctions of surplus assets from Pfizer's facilities across the United States. Over 500 lots per week will be available via online auction as part of GoIndustry DoveBid's ongoing BioPharma Exchange, over the upcoming months.
(Logo: http://photos.prnewswire.com/prnh/20100630/PH28915LOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20100630/PH28915LOGO )
Each week's auction will include an outstanding selection of assets ranging from HPLC and NMR Systems to Mass Spectrometers and general lab equipment. The majority of assets come from working environments and have been maintained, as one would expect from a top tier company such as Pfizer.
"With GoIndustry DoveBid, we have undergone an extensive project to identify all the surplus assets in our facilities across the country," said Bill Carr, Asset Disposition Director, from Pfizer Inc. "We have been pleased with our past results and look forward to our upcoming participation in the BioPharma Exchange."
The GoIndustry DoveBid BioPharma Exchange is a weekly series of online auction sales. Buyers typically have 24 to 48 hours to bid on state-of-the-art, biotech lab, research & development, and pharmaceutical equipment from the world's leading pharmaceutical manufacturers including Pfizer, Merck, and Bristol-Myers Squibb Company.
The BioPharma exchanges -- featuring high quality Pfizer equipment -- are conducted weekly. For more information visit http://www.go-dove.com/exchanges/BioPharma.
To learn more about the Pfizer equipment available, contact Tom Laster at [email protected] or telephone: +1 (650) 377-2646
Further information and interviews available on request
About GoIndustry DoveBid & Pfizer
GoIndustry DoveBid continues to provide asset management services for Pfizer, supporting the company's ongoing global assets recovery efforts. As a result of this relationship, Pfizer has reduced the number of surplus assets; experienced cost savings due to internal redeployment of equipment globally; and benefited from welcome cash injections from external sales. Over the past 7 years, several business units -- from Animal Health to Pfizer Global Research & Development and Global Manufacturing -- have taken advantage of this full service relationship.
GoIndustry DoveBid works with the business units to help identify surplus assets. Our expert team provides market intelligence to facilitate whether the assets are made available for redeployment internally, or for sale externally. At which point assets are appraised to give an indication their market value.
GoIndustry DoveBid offers a wide range of options for external sale including: online Auction, Private Treaty sales, or industry specific Exchanges -- a weekly series of online auction sales. Pfizer continues to be a major player in the weekly BioPharma Exchange.
About GoIndustry DoveBid
GoIndustry DoveBid is a leading provider of asset management services. If surplus or idle assets are no longer needed, we help organizations understand their worth, whether they can be re-deployed elsewhere in the business, or sell them on the used industrial goods marketplace.
GoIndustry DoveBid approaches the market with three distinct advantages. First, we have significant global reach so we are able to provide these services wherever they are needed. Second, most of our business is online, making it more efficient and convenient for both buyers and sellers whether it's for a single piece of equipment or a whole production line. Third, our knowledge of the market across multiple industry sectors is unsurpassed. Since 2000, we have collected information gathered from auctions all over the world. We leverage this rich data on a daily basis through accurate valuations and appraisals for the benefit of all our customers.
Find out more about us at www.go-dove.com or contact us to unlock the value of your assets.
SOURCE GoIndustry DoveBid
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article